menu
    • menu
    [{"orgOrder":0,"company":"BioDlink","sponsor":"Undisclosed","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody, Unconjugated","year":"2025","type":"Inapplicable","leadProduct":"Bevacizumab","moa":"||Vascular endothelial growth factor A","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioDlink","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioDlink \/ Undisclosed","highestDevelopmentStatusID":"15","companyTruncated":"BioDlink \/ Undisclosed"},{"orgOrder":0,"company":"BioDlink","sponsor":"Lepu Biopharma","pharmaFlowCategory":"DU","therapeuticArea":"Oncology","country":"CHINA","productType":"Antibody-drug Conjugate","year":"2025","type":"Inapplicable","leadProduct":"Becotatug Vedotin","moa":"EGFR | Tubulin","graph1":"Oncology","graph2":"Approved FDF","graph3":"BioDlink","amount2":0,"highestDevelopmentShortName":"Approved FDF","therapeuticAreaShortName":"Oncology","amount2New":0,"dosageForm":"Infusion","sponsorNew":"BioDlink \/ BioDlink","highestDevelopmentStatusID":"15","companyTruncated":"BioDlink \/ BioDlink"}]

    Find Clinical Drug Pipeline Developments & Deals by BioDlink

    Menu

    BioDlink

    EVENTS

    • Webinars & Exhibitions

    DIGITAL CONTENT

    DEVELOPMENTS

    PharmaCompass
    Xls
    Filters Filter
    ×
    FILTER:
    filter
    Company Name
      filter

      Year

        filter

        DEALS // DEV.

          filter

          Country

            filter
            Sponsor
              filter

              Therapeutic Area

                filter

                Study Phase

                  filter

                  Deal Type

                    filter

                    Product Type

                      filter

                      Dosage Form

                        filter

                        Lead Product

                          filter

                          Target

                            Loading...
                            refresh Filters
                            refresh Reset Filter
                            refresh Reset Filter
                            price-trend All Developments

                            Therapeutic Area by Lead Product

                            Study Phase by Lead Product

                            Company by Lead Product

                            Top Deals by Deal Size (USD bn)

                            01

                            BioDlink

                            China arrow
                            COMPAMED
                            Not Confirmed

                            BioDlink

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Becotatug Vedotin

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Recipient : Lepu Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            Biodlink Congratulates Lepu Biopharma on World's First EGFR-Targeted ADC Approval

                            Details : Becotatug Vedotin, an antibody-drug conjugate targeting EGFR and Tubulin, shows promise in treating recurrent or metastatic nasopharyngeal carcinoma.

                            Product Name : Meiyouheng

                            Product Type : Antibody-drug Conjugate

                            Upfront Cash : Inapplicable

                            November 05, 2025

                            Lead Product(s) : Becotatug Vedotin

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Recipient : Lepu Biopharma

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth

                            02

                            BioDlink

                            China arrow
                            COMPAMED
                            Not Confirmed

                            BioDlink

                            China arrow
                            COMPAMED
                            Not Confirmed
                            • fda
                            • EDQM
                            • WHO-GMP
                            Virtual Booth Boost your online visibility by uploading your products, APIs, FDFs, intermediates, excipients, and services for free on PharmaCompass. Rank higher among suppliers and expand your reach across the internet efficiently and cost-effectively.

                            Lead Product(s) : Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Study Phase : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            DEALS_DEV arrow-down

                            BioDlink’s Bevacizumab Gets Indonesia Nod, Fourth Emerging Market OK

                            Details : Pusintin (bevacizumab) is a vascular endothelial growth factor-specific angiogenesis inhibitor indicated for the treatment of colorectal cancer & non-squamous non-small cell lung cancer.

                            Product Name : Pusintin

                            Product Type : Antibody, Unconjugated

                            Upfront Cash : Inapplicable

                            August 21, 2025

                            Lead Product(s) : Bevacizumab,Fluorouracil

                            Therapeutic Area : Oncology

                            Highest Development Status : Approved FDF

                            Sponsor : Undisclosed

                            Deal Size : Inapplicable

                            Deal Type : Inapplicable

                            blank

                            Stock Recap
                            #PipelineProspector

                            Data Compilation
                            #PharmaFlow

                            Virtual Booth